Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened versus standard chemoimmunotherapy for first-line high-tumor-burden follicular lymphoma
2024-511636-27-00Phase 3Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, obinutuzumab, cyclophosphamide, doxorubicin, vincristine and 4 more in follicular lymphoma (FL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Planned start Dec 2021; status: authorised.
02
Drugs
rituximabobinutuzumabcyclophosphamidedoxorubicinvincristine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2024-511636-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511636-27-00.